These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

241 related items for PubMed ID: 9703919

  • 21. Effects of the IMP-dehydrogenase inhibitor, Tiazofurin, in bcr-abl positive acute myelogenous leukemia. Part II. In vitro studies.
    Wright DG, Boosalis M, Malek K, Waraska K.
    Leuk Res; 2004 Nov; 28(11):1137-43. PubMed ID: 15380336
    [Abstract] [Full Text] [Related]

  • 22. Biochemical consequences of resistance to a recently discovered IMP dehydrogenase inhibitor, benzamide riboside, in human myelogenous leukemia K562 cells.
    Jayaram HN, O'Connor A, Grant MR, Yang H, Grieco PA, Cooney DA.
    J Exp Ther Oncol; 1996 Sep; 1(5):278-85. PubMed ID: 9414415
    [Abstract] [Full Text] [Related]

  • 23. Antitumor activity of 1-beta-D-arabinofuranosylcytosine conjugated with polyglutamic acid and its derivative.
    Kato Y, Saito M, Fukushima H, Takeda Y, Hara T.
    Cancer Res; 1984 Jan; 44(1):25-30. PubMed ID: 6197162
    [Abstract] [Full Text] [Related]

  • 24. Antitumor activity of P-4055 (elaidic acid-cytarabine) compared to cytarabine in metastatic and s.c. human tumor xenograft models.
    Breistøl K, Balzarini J, Sandvold ML, Myhren F, Martinsen M, De Clercq E, Fodstad O.
    Cancer Res; 1999 Jun 15; 59(12):2944-9. PubMed ID: 10383159
    [Abstract] [Full Text] [Related]

  • 25. Evaluation of the antitumor activity of 1-(3-C-ethynyl-beta-D-ribofuranosyl) (PJ272), a recent ribonucleoside analogue.
    Holl V, Jung P, Weltin D, Dauvergne J, Burger A, Coelho D, Dufour P, Aubertin AM, Bischoff PL, Biellmann JF.
    Anticancer Res; 2000 Jun 15; 20(3A):1739-42. PubMed ID: 10928102
    [Abstract] [Full Text] [Related]

  • 26.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 27. Biochemical and antitumor activity of tiazofurin and its selenium analog (2-beta-D-ribofuranosyl-4-selenazolecarboxamide).
    Boritzki TJ, Berry DA, Besserer JA, Cook PD, Fry DW, Leopold WR, Jackson RC.
    Biochem Pharmacol; 1985 Apr 01; 34(7):1109-14. PubMed ID: 3985993
    [Abstract] [Full Text] [Related]

  • 28.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 29. Role of human nucleoside transporters in the cellular uptake of two inhibitors of IMP dehydrogenase, tiazofurin and benzamide riboside.
    Damaraju VL, Visser F, Zhang J, Mowles D, Ng AM, Young JD, Jayaram HN, Cass CE.
    Mol Pharmacol; 2005 Jan 01; 67(1):273-9. PubMed ID: 15486050
    [Abstract] [Full Text] [Related]

  • 30.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 31.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 32. Synergistic effect of purine derivatives on the toxicity of pyrazofurin and 6-azauridine towards cultured mammalian cells.
    Gupta RS, Moffat MR.
    J Cell Physiol; 1982 Jun 01; 111(3):291-4. PubMed ID: 6178748
    [Abstract] [Full Text] [Related]

  • 33. Nucleosides and nucleotides. 175. Structural requirements of the sugar moiety for the antitumor activities of new nucleoside antimetabolites, 1-(3-C-ethynyl-beta-D-ribo-pentofuranosyl)cytosine and -uracil1.
    Hattori H, Nozawa E, Iino T, Yoshimura Y, Shuto S, Shimamoto Y, Nomura M, Fukushima M, Tanaka M, Sasaki T, Matsuda A.
    J Med Chem; 1998 Jul 16; 41(15):2892-902. PubMed ID: 9667977
    [Abstract] [Full Text] [Related]

  • 34. Modulation of nicotinamide adenine dinucleotide and poly(adenosine diphosphoribose) metabolism by the synthetic "C" nucleoside analogs, tiazofurin and selenazofurin. A new strategy for cancer chemotherapy.
    Berger NA, Berger SJ, Catino DM, Petzold SJ, Robins RK.
    J Clin Invest; 1985 Feb 16; 75(2):702-9. PubMed ID: 3919063
    [Abstract] [Full Text] [Related]

  • 35. Tricyclic pyrone analogs: a new synthetic class of bifunctional anticancer drugs that inhibit nucleoside transport, microtubule assembly, the viability of leukemic cells in vitro and the growth of solid tumors in vivo.
    Perchellet EM, Ladesich JB, Magill MJ, Chen Y, Hua DH, Perchellet JP.
    Anticancer Drugs; 1999 Jun 16; 10(5):489-504. PubMed ID: 10477169
    [Abstract] [Full Text] [Related]

  • 36.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 37.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 38. Synthesis, cytotoxicity and antitumor activity of some new simplified pyrazole analogs of the antitumor agent CC-1065. Effect of an hydrophobic group on antitumor activity.
    Baraldi PG, Cacciari B, Guiotto A, Romagnoli R, Spalluto G, Zaid AN, Cozzi P, Geroni C, Mongelli N.
    Farmaco; 1997 Dec 16; 52(12):711-6. PubMed ID: 9648274
    [Abstract] [Full Text] [Related]

  • 39. Synergistic inhibition of leukemia L1210 cell growth in vitro by combinations of 2-fluoroadenine nucleosides and hydroxyurea or 2,3-dihydro-1H-pyrazole[2,3-a]imidazole.
    Sato A, Montgomery JA, Cory JG.
    Cancer Res; 1984 Aug 16; 44(8):3286-90. PubMed ID: 6611198
    [Abstract] [Full Text] [Related]

  • 40. Furanfurin and thiophenfurin: two novel tiazofurin analogues. Synthesis, structure, antitumor activity, and interactions with inosine monophosphate dehydrogenase.
    Franchetti P, Cappellacci L, Grifantini M, Barzi A, Nocentini G, Yang H, O'Connor A, Jayaram HN, Carrell C, Goldstein BM.
    J Med Chem; 1995 Sep 15; 38(19):3829-37. PubMed ID: 7562914
    [Abstract] [Full Text] [Related]

    Page: [Previous] [Next] [New Search]
    of 13.